Jean Lacau St Guily1, Alexandra Rousseau2, Bertrand Baujat3, Sophie Périé4, Philippe Schultz5, Béatrix Barry6, Xavier Dufour7, Olivier Malard8, Jean-Luc Pretet9, Christine Clavel10, Philippe Birembaut11, Silvia Franceschi12. 1. Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Otolaryngology-Head and Neck Surgery, Tenon Hospital, 75020 Paris, France; Pierre-et-Marie Curie University - Sorbonne Universities, University Cancerology Institute UPMC, Paris, France. Electronic address: jean.lacau@aphp.fr. 2. Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Clinical Pharmacology and Clinical Research Unit of East of Paris (URC-Est), Saint Antoine Hospital, 75012 Paris, France. Electronic address: alexandra.rousseau@aphp.fr. 3. Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Otolaryngology-Head and Neck Surgery, Tenon Hospital, 75020 Paris, France; Pierre-et-Marie Curie University - Sorbonne Universities, University Cancerology Institute UPMC, Paris, France. Electronic address: bertrand.baujat@tnn.aphp.fr. 4. Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Otolaryngology-Head and Neck Surgery, Tenon Hospital, 75020 Paris, France; Pierre-et-Marie Curie University - Sorbonne Universities, University Cancerology Institute UPMC, Paris, France. Electronic address: sophie.perie@tnn.aphp.fr. 5. Department of Otolaryngology-Head and Neck Surgery, Strasbourg University Hospital - Hautepierre, 67098 Strasbourg Cedex, France. Electronic address: philippe.schultz@chru-strasbourg.fr. 6. Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Otolaryngology-Head and Neck Surgery, Bichat Hospital, and University-Paris 7, 75877 Paris Cedex 18, France. Electronic address: beatrix.barry@bch.aphp.fr. 7. Department of Otolaryngology-Head and Neck Surgery, Poitiers University Hospital, 86021 Poitiers Cedex, France. Electronic address: xavier.dufour@chu-poitiers.fr. 8. Department of Otolaryngology-Head and Neck Surgery, Nantes University Hospital - Hotel-Dieu, 44093 Nantes Cedex 1, France. Electronic address: olivier.malard@chu-nantes.fr. 9. Franche-Comte University, COMUE UBFC, Besançon University Hospital - Jean Minjoz, 25030 Besançon Cedex, France; Inserm CIC 1431, 25030 Besançon Cedex, France. Electronic address: jean_luc.pretet@univ-fcomte.fr. 10. INSERM UMR-S903, Reims University Hospital - Maison Blanche, 51092 Reims Cedex, France. Electronic address: cclavel@chu-reims.fr. 11. Laboratory of Biopathology, Reims University Hospital - Maison Blanche, Reims-Champagne-Ardenne University, 51092 Reims Cedex, France. Electronic address: pbirembaut@chu-reims.fr. 12. International Agency for Research on Cancer, 150 Cours Albert Thomas, 69372 Lyon Cedex 08, France. Electronic address: franceschi@iarc.fr.
Abstract
AIMS: To evaluate the impact of human papillomavirus (HPV) status, tobacco smoking and initial treatment approach on progression-free survival (PFS) and overall survival (OS) for oropharyngeal cancer (OPC) in France, a country where smoking declines started late (1990s). METHODS: 340 OPC patients (median age: 60years) from 14 French hospitals were followed up (median 26.7months). PCR-based positivity for both HPV DNA and E6/E7 mRNA was used to distinguish HPV-positive OPC (27.1%). Hospital-stratified hazard ratios (HR) and corresponding 95% confidence intervals (CI) were used to compare PFS and OS according to HPV and other prognostic factors in hospital-stratified unadjusted and multivariate models. The combined effect of HPV status with either smoking, stage, or initial treatment on PFS was also evaluated. RESULTS: PFS in multivariate analysis was better in HPV-positive patients (HR=0.42; 95% CI: 0.24-0.73) and worse in older patients (HR for 5-year age increase=1.12) and those having had firstly radiotherapy (HR=1.86; 95% CI: 1.19-2.92) or induction chemotherapy (HR=1.73; 95% CI: 1.08-2.79) instead of upfront surgery. Findings for OS were similar. Loco-regional recurrences were less frequent in HPV-positive (10.5%) than HPV-negative patients (26.0%) but distant recurrences were similarly frequent. HPV status did not modify the influence of smoking or stage on PFS but the impossibility to perform upfront surgery may be more relevant for HPV-negative patients. CONCLUSIONS: HPV-positive OPC patients fare better than HPV-negative OPC and may benefit from toxicity-sparing. Whether HPV-negative patients responded less well to radiation and chemotherapy because of more severe genomic damage or bulkier tumours is unclear.
AIMS: To evaluate the impact of human papillomavirus (HPV) status, tobacco smoking and initial treatment approach on progression-free survival (PFS) and overall survival (OS) for oropharyngeal cancer (OPC) in France, a country where smoking declines started late (1990s). METHODS: 340 OPC patients (median age: 60years) from 14 French hospitals were followed up (median 26.7months). PCR-based positivity for both HPV DNA and E6/E7 mRNA was used to distinguish HPV-positive OPC (27.1%). Hospital-stratified hazard ratios (HR) and corresponding 95% confidence intervals (CI) were used to compare PFS and OS according to HPV and other prognostic factors in hospital-stratified unadjusted and multivariate models. The combined effect of HPV status with either smoking, stage, or initial treatment on PFS was also evaluated. RESULTS: PFS in multivariate analysis was better in HPV-positive patients (HR=0.42; 95% CI: 0.24-0.73) and worse in older patients (HR for 5-year age increase=1.12) and those having had firstly radiotherapy (HR=1.86; 95% CI: 1.19-2.92) or induction chemotherapy (HR=1.73; 95% CI: 1.08-2.79) instead of upfront surgery. Findings for OS were similar. Loco-regional recurrences were less frequent in HPV-positive (10.5%) than HPV-negative patients (26.0%) but distant recurrences were similarly frequent. HPV status did not modify the influence of smoking or stage on PFS but the impossibility to perform upfront surgery may be more relevant for HPV-negative patients. CONCLUSIONS:HPV-positive OPC patients fare better than HPV-negative OPC and may benefit from toxicity-sparing. Whether HPV-negative patients responded less well to radiation and chemotherapy because of more severe genomic damage or bulkier tumours is unclear.
Authors: François Cherifi; Maud Villemin; Frederique Bisiaux; Alison Johnson; Heidi Solem Laviec; Audrey Rambeau Journal: Support Care Cancer Date: 2022-04-27 Impact factor: 3.603
Authors: Jean-Luc Prétet; Véronique Dalstein; Antoine Touzé; Agnès Beby-Defaux; Patrick Soussan; Élise Jacquin; Philippe Birembaut; Christine Clavel; Christiane Mougin; Alexandra Rousseau; Jean Lacau Saint Guily Journal: Clin Exp Med Date: 2022-02-23 Impact factor: 3.984
Authors: Philippe Gorphe; Pierre Blanchard; Gabriel C T E Garcia; Marion Classe; Caroline Even; Stéphane Temam; Ingrid Breuskin Journal: BMC Cancer Date: 2022-09-20 Impact factor: 4.638
Authors: Faris F Brkic; Stefan Stoiber; Tobias Maier; Elisabeth Gurnhofer; Lukas Kenner; Gregor Heiduschka; Lorenz Kadletz-Wanke Journal: Pharmaceuticals (Basel) Date: 2022-03-20